Edwards Lifesciences Corporation $EW Shares Bought by HighTower Advisors LLC

HighTower Advisors LLC lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 20.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 134,112 shares of the medical research company’s stock after acquiring an additional 22,977 shares during the period. HighTower Advisors LLC’s holdings in Edwards Lifesciences were worth $10,430,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. True Wealth Design LLC increased its stake in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the last quarter. NewSquare Capital LLC boosted its holdings in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares during the period. Hantz Financial Services Inc. grew its position in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after buying an additional 164 shares during the last quarter. Rakuten Securities Inc. raised its stake in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the period. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in Edwards Lifesciences during the third quarter worth about $30,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Trading Up 1.2%

NYSE:EW opened at $79.88 on Friday. The stock has a market cap of $46.35 billion, a price-to-earnings ratio of 43.65, a PEG ratio of 2.08 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The business has a fifty day moving average of $82.80 and a 200-day moving average of $81.03.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This trade represents a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 43,804 shares of company stock worth $3,699,082 over the last quarter. 1.29% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on EW. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a report on Monday, November 3rd. Piper Sandler restated an “overweight” rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Mizuho increased their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Jefferies Financial Group set a $98.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Evercore restated an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 5th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.